pharmacology services 

We understand the importance of determining as soon as possible if your test article is efficacious for its intended use to avoid failures further down the development path. Our global pharmacology team conducts early research and proof-of-principle studies in relevant animal models of human diseases to assist your safety and efficacy evaluations.

Our library of pharmacology models span the following areas:

• Oncology: In vivo models include human tumor xenograft, syngeneic, metastatic, orthotopic, and genetically engineered models. These models are augmented with the use of preclinical imaging technologies (such as PET, MRI, CT, and bioluminescence) and expertise in IC₅₀ determination, combination chemotherapy, radiation therapy, angiogenesis, biomarker, and pharmacodynamic assessment.
• Metabolic diseases: Efficacy screening can be conducted in models of diabetes mellitus, obesity, hyperlipidemia, renal diseases, and inflammatory bowel disease, among others.
• Cardiovascular diseases: Compound efficacy testing is performed in models of atherosclerosis and hypertension, among others.
• Respiratory diseases: Efficacy models include asthma, airway hyperresponsiveness, and chronic obstructive pulmonary disease.
• Inflammatory diseases: Efficacy testing is available in models of rheumatoid arthritis, experimental allergic encephalitis, inflammatory bowel disease, asthma, delayed type hypersensitivity, peritonitis, LPS-induced cytokine release, T cell-dependent antibody response, and sponge granuloma, among others.
• Neurology: Models include experimental allergic encephalitis, epilepsy, pain, locomotor, and cognitive disorders.
• Orthopedics: Models span from osteoporosis and osteoarthritis to rheumatoid arthritis and are complemented by DEXA and CT imaging, biomarker, biomechanical bone strength testing, and histopathology services.
• Ocular
• Infectious diseases
• Organ transplantation
• Dermal
• Tissue repair and wound healing